痛風治療薬の世界市場レポート 2024

痛風治療薬の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には11.5%の年間複合成長率（CAGR）で44億1,000万米ドルに成長すると予想されます。予測期間で予想される成長は、ヘルスケアの増加、ドラッグデリバリーシステムの進歩、新しい治療法の出現、慢性疾患管理を目的とした政府の取り組み、患者擁護団体や支援団体の存在に起因すると考えられます。予測期間に予想される主な動向には、革新的な医薬品の開発、新薬の承認、個別化医療におけるアプローチ、痛風管理のための遠隔医療サービスの提供、尿酸降下療法における進行中の調査が含まれます。

痛風治療薬市場の予想される成長は、痛風の発生の増加によって促進されると予想されます。関節の痛みや腫れを引き起こす炎症性関節炎を特徴とする痛風は、痛風治療薬によって効果的に治療され、影響を受けた関節の痛み、腫れ、圧痛が軽減されます。痛風の発生率の増加は、市場の成長に貢献する態勢が整っています。たとえば、2022年9月の英国国民保健サービスの報告書によると、2021年から2022年の間に英国の病院で記録された新規痛風の症例は20%増加し、合計25万件に達したとのことです。したがって、痛風の発生率の上昇傾向は、痛風治療薬市場の成長の重要な推進力となります。

肥満の蔓延により、今後数年間で痛風治療薬市場の拡大が促進されると予想されます。体脂肪の異常な蓄積を特徴とする肥満は、痛風の発症と悪化の主要な危険因子と考えられています。肥満は痛風の発作の頻度と重症度を高め、その管理に課題を引き起こす可能性があります。世界保健機関の2022年 3月の報告書によると、世界中で10億人以上の人々（青少年 3億4,000万人、子供3,900万人、成人 6億5,000万人）が肥満の影響を受けています。肥満の有病率は増加し続けており、WHOの予測では、2025年までに1億6,700万人の成人と子供が過体重または肥満により健康被害に直面するとされています。したがって、肥満の蔓延が痛風治療薬市場の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の痛風治療薬市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 非ステロイド性抗炎症薬（NSAID）
• コルチコステロイド
• 利尿薬
• 世界の痛風治療薬市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• キサンチンオキシダーゼ阻害剤
• 尿酸尿症の治療薬
• 世界の痛風治療薬市場、病状別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 急性
• 慢性
• 世界の痛風治療薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 専門クリニック
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の痛風治療薬市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の痛風治療薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 痛風治療薬市場の競合情勢
• 痛風治療薬市場の企業プロファイル
  • AbbVie Inc.
  • Sanofi-Aventis
  • AstraZeneca plc
  • LG Chem Ltd.
  • GlaxoSmithKline Plc

第31章 その他の大手および革新的な企業

• Takeda Pharmaceuticals Co. Ltd.
• Boehringer Ingelheim International GmbH
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Sandoz
• Eisai Co. Ltd.
• Horizon Pharma Plc
• Jiangsu HengRui Medicine Co. Ltd.
• Hikma Pharmaceuticals plc
• Swedish Orphan Biovitrum AB
• JW Pharmaceutical Corp
• Lannett Company Inc
• BioCryst Pharmaceuticals Inc.
• Selecta Biosciences Inc.
• Rigel Pharmaceuticals Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Gout therapeutics encompass medications designed to exert therapeutic effects in addressing the medical condition known as gout, or inflammatory arthritis, characterized by pain and swelling in joints. These therapeutics aim to treat and alleviate pain, swelling, and tenderness associated with gout.

The primary categories of gout therapeutics include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and diuretics. Non-steroidal anti-inflammatory drugs (NSAIDs) are medications employed to reduce inflammation, relieve pain, and lower elevated body temperatures. Treatment options encompass xanthine oxidase inhibitors and uricosuria medications tailored for various disease conditions, including both acute and chronic cases. These therapeutics find application across various end-users, including hospitals, specialty clinics, and others.

The gout therapeutics market research report is one of a series of new reports from The Business Research Company that provides gout therapeutics market statistics, including gout therapeutics industry global market size, regional shares, competitors with a gout therapeutics market share, detailed gout therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the gout therapeutics industry. This gout therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gout therapeutics market size has grown rapidly in recent years. It will grow from $2.54 billion in 2023 to $2.86 billion in 2024 at a compound annual growth rate (CAGR) of 12.7%. The growth observed in the historic period can be attributed to factors such as the increased prevalence of gout, shifts in lifestyle and dietary patterns, elevated rates of high blood pressure and diabetes, the development of xanthine oxidase inhibitors, and initiatives focused on educating patients.

The gout therapeutics market size is expected to see rapid growth in the next few years. It will grow to $4.41 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The anticipated growth in the forecast period can be attributed to increasing healthcare expenditure, advancements in drug delivery systems, the emergence of novel therapies, government initiatives aimed at chronic disease management, and the presence of patient advocacy and support groups. Major trends expected in the forecast period include innovative drug development, approvals for novel drugs, approaches in personalized medicine, the provision of telehealth services for gout management, and ongoing research in urate-lowering therapies.

The anticipated growth in the gout therapeutics market is expected to be driven by the rising occurrence of gout. Gout, characterized by inflammatory arthritis causing pain and swelling in joints, is effectively treated by gout therapeutics, providing relief from pain, swelling, and tenderness in affected joints. The increasing incidence of gout is poised to contribute to the market's growth. For instance, reports from the UK's National Health Service in September 2022 revealed a 20% increase in new gout cases recorded in British hospitals between 2021 and 2022, totaling 250,000 cases. Consequently, the upward trend in gout incidence is a significant driver for the growth of the gout therapeutics market.

The growing prevalence of obesity is anticipated to fuel the expansion of the gout therapeutics market in the years to come. Obesity, characterized by an abnormal accumulation of body fat, is considered a major risk factor for the onset and exacerbation of gout. Obesity can intensify the frequency and severity of gout attacks, posing challenges in their management. According to the World Health Organization's March 2022 report, over 1 billion individuals globally, including 340 million adolescents, 39 million children, and 650 million adults, are affected by obesity. The prevalence of obesity continues to rise, with WHO projections indicating that by 2025, 167 million adults and children will face health consequences due to being overweight or obese. Therefore, the increasing prevalence of obesity stands as a driving force for the gout therapeutics market.

Product innovation is a prominent trend gaining traction in the gout therapeutics market, with major companies actively engaged in developing innovative treatments to maintain their competitive edge. An example of such innovation is seen in the August 2022 launch of SYNB2081 by Synlogic Inc., a US-based pharmaceutical company. SYNB2081, a synthetic biotic, represents a novel drug candidate designed for gout treatment, specifically aimed at lowering uric acid levels. This development is the outcome of a collaborative research effort between Synlogic and Ginkgo, a US-based biotech company.

Major companies in the gout therapeutics market are focusing on the development of innovative products, such as corticotropin. Corticotropin, also known as adrenocorticotropic hormone (ACTH), is a peptide hormone secreted by the anterior pituitary gland in response to low cortisol levels in the blood. An illustration of this is seen in the January 2022 launch of Purified Cortrophin Gel (Repository Corticotropin Injection USP) 80 U/mL by ANI Pharmaceuticals, Inc., a US-based pharmaceutical company. This gel, an adrenocorticotropic hormone (ACTH), is marketed by ANI's newly established rare illness business unit and is used in the treatment of chronic autoimmune conditions such as acute exacerbations of multiple sclerosis (MS) and gouty arthritis (GA), as well as excess urine protein due to nephrotic syndrome.

In December 2022, Innovent Biologics, a China-based biopharmaceutical company, and LG Chem Life Sciences, a US-based pharmaceutical company, forged a strategic collaboration and license agreement for LG Chem's Tigulixostat, intended for the chronic management of hyperuricemia in patients with gout disease. This partnership grants Innovent exclusive rights to develop and commercialize Tigulixostat in China for $95.5 million, encompassing a $10 million upfront payment. LG Chem stands to receive milestones and tiered royalties based on net product sales in China. Tigulixostat, a novel xanthine oxidase inhibitor, targets the reduction of uric acid in purine metabolism, showcasing a therapeutic intervention for gout.

Major companies operating in the gout therapeutics market report are AbbVie Inc., Sanofi-Aventis, AstraZeneca PLC, LG Chem Ltd., GlaxoSmithKline PLC, Takeda Pharmaceuticals Co. Ltd., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Sandoz, Eisai Co. Ltd., Horizon Pharma PLC, Jiangsu HengRui Medicine Co. Ltd., Hikma Pharmaceuticals PLC, Swedish Orphan Biovitrum AB, JW Pharmaceutical Corp, Lannett Company Inc., BioCryst Pharmaceuticals Inc., Selecta Biosciences Inc., Rigel Pharmaceuticals Inc., Avion Pharmaceuticals LLC, Protalix BioTherapeutics Inc., Teijin Pharma Limited, Romeg Therapeutics LLC., CymaBay Therapeutics Inc., GeneScience Pharmaceuticals Co. Ltd., Shanton Pharma

North America was the largest region in the gout therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gout therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gout therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gout therapeutics market consists of the sales of allopurinol, benzbromarone, febuxostat, probenecid, and pegloticase drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gout Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gout therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gout therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gout therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroid; Diuretics
• 2) By Treatment: Xanthine Oxidase Inhibitor; Uricosuria Medication
• 3) By Disease Condition: Acute; Chronic
• 4) By End-Users: Hospitals; Specialty Clinics; Other End Users
• Companies Mentioned: AbbVie Inc.; Sanofi-Aventis; AstraZeneca plc; LG Chem Ltd.; GlaxoSmithKline Plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gout Therapeutics Market Characteristics

3. Gout Therapeutics Market Trends And Strategies

4. Gout Therapeutics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Gout Therapeutics Market Size and Growth

• 5.1. Global Gout Therapeutics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Gout Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Gout Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Gout Therapeutics Market Segmentation

• 6.1. Global Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroid
• Diuretics
• 6.2. Global Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Xanthine Oxidase Inhibitor
• Uricosuria Medication
• 6.3. Global Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Acute
• Chronic
• 6.4. Global Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Specialty Clinics
• Other End Users

7. Gout Therapeutics Market Regional And Country Analysis

• 7.1. Global Gout Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Gout Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Gout Therapeutics Market

• 8.1. Asia-Pacific Gout Therapeutics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Gout Therapeutics Market

• 9.1. China Gout Therapeutics Market Overview
• 9.2. China Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Gout Therapeutics Market

• 10.1. India Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Gout Therapeutics Market

• 11.1. Japan Gout Therapeutics Market Overview
• 11.2. Japan Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Gout Therapeutics Market

• 12.1. Australia Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Gout Therapeutics Market

• 13.1. Indonesia Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Gout Therapeutics Market

• 14.1. South Korea Gout Therapeutics Market Overview
• 14.2. South Korea Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Gout Therapeutics Market

• 15.1. Western Europe Gout Therapeutics Market Overview
• 15.2. Western Europe Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Gout Therapeutics Market

• 16.1. UK Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Gout Therapeutics Market

• 17.1. Germany Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Gout Therapeutics Market

• 18.1. France Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Gout Therapeutics Market

• 19.1. Italy Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Gout Therapeutics Market

• 20.1. Spain Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Gout Therapeutics Market

• 21.1. Eastern Europe Gout Therapeutics Market Overview
• 21.2. Eastern Europe Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Gout Therapeutics Market

• 22.1. Russia Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Gout Therapeutics Market

• 23.1. North America Gout Therapeutics Market Overview
• 23.2. North America Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Gout Therapeutics Market

• 24.1. USA Gout Therapeutics Market Overview
• 24.2. USA Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Gout Therapeutics Market

• 25.1. Canada Gout Therapeutics Market Overview
• 25.2. Canada Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Gout Therapeutics Market

• 26.1. South America Gout Therapeutics Market Overview
• 26.2. South America Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Gout Therapeutics Market

• 27.1. Brazil Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Gout Therapeutics Market

• 28.1. Middle East Gout Therapeutics Market Overview
• 28.2. Middle East Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Gout Therapeutics Market

• 29.1. Africa Gout Therapeutics Market Overview
• 29.2. Africa Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Gout Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Gout Therapeutics Market Competitive Landscape
• 30.2. Gout Therapeutics Market Company Profiles
  • 30.2.1. AbbVie Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Sanofi-Aventis
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. AstraZeneca plc
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. LG Chem Ltd.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. GlaxoSmithKline Plc
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Gout Therapeutics Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceuticals Co. Ltd.
• 31.2. Boehringer Ingelheim International GmbH
• 31.3. Regeneron Pharmaceuticals Inc.
• 31.4. Astellas Pharma Inc.
• 31.5. Sandoz
• 31.6. Eisai Co. Ltd.
• 31.7. Horizon Pharma Plc
• 31.8. Jiangsu HengRui Medicine Co. Ltd.
• 31.9. Hikma Pharmaceuticals plc
• 31.10. Swedish Orphan Biovitrum AB
• 31.11. JW Pharmaceutical Corp
• 31.12. Lannett Company Inc
• 31.13. BioCryst Pharmaceuticals Inc.
• 31.14. Selecta Biosciences Inc.
• 31.15. Rigel Pharmaceuticals Inc.

32. Global Gout Therapeutics Market Competitive Benchmarking

33. Global Gout Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Gout Therapeutics Market

35. Gout Therapeutics Market Future Outlook and Potential Analysis

• 35.1 Gout Therapeutics Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Gout Therapeutics Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Gout Therapeutics Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer